BioNTech’s Bold New Step into Cancer Treatments Amid Financial Setbacks
BioNTech shifts focus from COVID-19 vaccines to pioneering mRNA-based cancer therapies to combat revenue decline. Despite a sharp drop in earnings, from €9.4 billion in 2022 to €930 million in…